Retatrutide 10 mg — Research Consultation
Retatrutide is a synthetic triple-receptor agonist studied in the published metabolic-research literature. The molecule binds and activates three endogenous receptor classes (GLP-1, GIP, glucagon) and is being investigated for its effects on glucose homeostasis, hepatic lipid metabolism, and energy expenditure. This page summarises the mechanism and links you into an in-chat research consultation with Nour.
What retatrutide is
Retatrutide is a synthetic peptide engineered to activate three receptor classes simultaneously: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Each of these receptors has its own well-characterised endogenous ligand and physiological role. Triple-agonist molecules are a research class that is distinct from single- or dual-receptor agonist research — researchers reading the literature should be careful to distinguish triple-agonist publications from the broader incretin-agonist literature.
What the published research covers
Published preclinical and early-phase clinical research describes retatrutide pharmacology, receptor-binding affinities at each of the three target receptors, and pharmacokinetic profiles in animal and human studies. Endpoints in the published literature span glucose homeostasis, hepatic lipid metabolism (including measures of liver fat content), and energy expenditure. The research base is small relative to single-receptor agonist research and is still evolving — researchers should be cautious about extrapolating early-phase findings.
Pharmacokinetic profile
Retatrutide has a long terminal half-life reported in the published human pharmacokinetic studies, supporting once-weekly research administration in published protocols. Researchers studying receptor-class pharmacology should consult the pharmacokinetic publications before committing to a protocol — and Nour can pull the relevant references in the chat.
Quality verification
Lyophilised retatrutide 10 mg manufactured under ICH Q7 GMP standards, with independent HPLC verification at a US-based third-party laboratory. Peak-area purity ≥98% at λ=214 nm against pharmacopoeia reference standards. Each released batch carries a Certificate of Analysis available through the in-chat consultation. Each shipment includes the storage and handling guidance for your batch.
Talk to Nour before you commit
Nour walks through what the published research literature actually shows, the pharmacokinetic considerations, the difference between triple-receptor agonist research and other GLP-class research, and whether retatrutide fits your research question. English or Arabic, free, no commitment.
Common research questions
- Is retatrutide legal in the UAE?
- Retatrutide is classified as a research compound in the UAE and is sold through standard wellness-supply channels. Wellness Labs operates under standard UAE commercial trading rules with VAT compliance applied to every dispatch. Customers purchase for self-directed research use under their own protocol.
- What does "triple-receptor agonist" mean?
- It means the molecule binds and activates three distinct receptor classes — GLP-1, GIP, and glucagon — rather than just one or two. Each of these receptors has its own endogenous ligand and signalling pathway. The triple-agonist research class is distinct from single- or dual-agonist research molecules in the published literature.
- What dosing does the published research describe?
- Published early-phase human pharmacology studies describe dose-titration schedules over multiple weeks, starting from low doses and escalating gradually. The pharmacokinetic profile supports once-weekly administration in published protocols. Specific dosing depends on the research question — Nour can walk through the published protocols in the chat.
- What are the reported side-effect signals?
- Published early-phase studies have reported gastrointestinal signals (nausea, transient discomfort) particularly during dose-escalation phases. These signals are consistent with the broader GLP-class research literature. Researchers should consult the published safety data before committing to a protocol.
- How is retatrutide reconstituted?
- Lyophilised retatrutide is reconstituted with bacteriostatic water at the researcher's chosen concentration. Storage and handling guidance accompanies every shipment. Nour can walk through the reconstitution math in the chat.
- How is purity verified?
- Every released batch ships with a Certificate of Analysis showing HPLC peak-area purity (≥98%) at a US-based third-party laboratory, against pharmacopoeia reference standards. Method specifications are published on our quality page.
- Shelf life and storage?
- Lyophilised retatrutide is ambient-temperature stable in transit. Long-term storage of the lyophilised powder at -20°C protected from light. After reconstitution, refrigerated storage with appropriate handling per the supplied protocol.
- How fast is delivery in the UAE?
- Same-day delivery within Dubai, next-business-day across the rest of the UAE.
- Can I ask Nour about my specific research protocol?
- Yes. Tap "Start a research consultation". Nour reads the peer-reviewed literature and walks through the protocol options based on your research question.
Peer-reviewed references
Related consultations
Further reading
Talk to Nour about your research protocol
Nour reads the peer-reviewed literature and walks you through what each compound is best suited for. English or Arabic, inside the chat.